The Eczema Therapeutics Market research report presents a complete and concise global market study. It offers quantitative and qualitative information on the entire industry structure. This Eczema Therapeutics research report delivers an overview of the market based on the segmentation, which helps the client easily understand the need. The markets are expected to depict a […]
On Jan. 14, AbbVie‘s (NYSE:ABBV) Rinvoq received approval from the U.S. Food and Drug Administration (FDA) to treat adults and children at least 12 years old with moderate-to-severe atopic dermatitis (eczema) whose condition didn’t respond to other medicines. What led the FDA to approve Rinvoq for its third indication? And how much of a boost […]
In mid-January, Pfizer (NYSE:PFE) announced that the U.S. Food and Drug Administration (FDA) gave the nod to Cibinqo as a treatment for patients with moderate to severe atopic dermatitis (eczema) whose disease wasn’t adequately controlled with other treatments. Why did the FDA approve Cibinqo for moderate to severe eczema patients? And what could this mean […]